Qlaris Bio
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Qlaris Bio sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Qlaris Bio: 8 sponsored US clinical trials, 2 recruiting.
Qlaris Bio sponsors 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Normal Tension Glaucoma (NTG), with 1 trials.
Upper-quartile sponsor footprint
Qlaris Bio sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
NCT07354516
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
NCT07354477
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
NCT06249152
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
NCT06016972
Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)
NCT05495269
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
NCT04947124
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
NCT04857827
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
NCT04830397
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 8 |
What is open in the Qlaris Bio pipeline
2 recruiting of 8 indexed (25% open); 6 completed (75%).
Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Normal Tension Glaucoma (NTG) (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Qlaris Bio: open-pipeline peers nationwide
Peers matched on 8 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Qlaris Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 25% open enrollment (± trial volume)
- Abdul Latif Jameel Poverty Action Lab · 25% recruiting · 4 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
- Advocate Hospital System · 25% recruiting · 4 trials
Related
What to do with this Qlaris Bio page
8 registered trials is a research-attention snapshot, not an endorsement of Qlaris Bio or any single study.
- 2 of Qlaris Bio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Normal Tension Glaucoma (NTG) is the condition Qlaris Bio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Normal Tension Glaucoma (NTG) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Qlaris Bio pipeline card: 8 registered trials from official public datasets.Report a data error.